Plasma copeptin and functional outcome in patients with ischemic stroke and type 2 diabetes

BackgroundThe activation of the arginine vasopressin system may be involved in the pathology of stroke and diabetes. In this study, we therefore evaluated the short-term prognostic value of early measurement of plasma copeptin levels in Chinese patients with type 2 diabetes mellitus (T2DM) and acute ischemic stroke (AIS).MethodsFrom July 2014 to June 2015, all T2DM patients with first-ever AIS were included. Plasma levels of copeptin were tested at admission. The prognostic value of copeptin to predict the functional outcome and mortality 3 months after stroke was compared with the National Institutes of Health Stroke Scale score and with other known outcome predictors.ResultsWe recorded 247 stroke patients with T2DM. The copeptin levels were obtained in those patients with a median value of 14.3 pmol/L (IQR, 9.5-17.1 pmol/L). At 3-month follow-up, a favorable functional outcome was found in 86 patients (34.8%). Plasma copeptin levels in patients with an unfavorable outcome were significantly greater than those in patients with a favorable outcome (16.2 [IQR, 12.2-20.3] vs. 12.4 [IQR, 8.6-15.2] pmol/L; Z = 5.399; P < 0.0001). In univariate logistic regression analysis, with an unadjusted OR of 1.123 (95% CI, 1.072-1.177, P < 0.001), copeptin had a strong association with unfavorable functional outcome. In multivariate analyses, a copeptin level in the highest inter-quartile (> 17.1 pmol/L) was associated with a higher risk of unfavorable functional outcome (OR = 4.62; 95% CI = 2.63-9.21; P < 0.001). After adjusting for other outcome predictors, a copeptin level in the highest inter-quartile (> 17.1 pmol/L) was associated with a higher risk of mortality (OR = 5.12; 95% CI = 2.20-11.38; P < 0.001).ConclusionOur study suggested that copeptin levels may reliably predict short-term stroke prognosis at its onset in Chinese patients with T2DM and stroke.